An optimized cyclophosphamide-treated mouse model of Mycobacterium abscessus pulmonary infection

Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0152023. doi: 10.1128/aac.01520-23. Epub 2024 Jul 11.

Abstract

Mycobacterium abscessus pulmonary infections are increasingly problematic, especially for immunocompromised individuals and those with underlying lung conditions. Currently, there is no reliable standardized treatment, underscoring the need for improved preclinical drug testing. We present a simplified immunosuppressed mouse model using only four injections of cyclophosphamide, which allows for sustained M. abscessus lung burden for up to 16 days. This model proved effective for antibiotic efficacy evaluation, as demonstrated with imipenem or amikacin.

Keywords: M. abscessus; lung infection; mouse model.

MeSH terms

  • Amikacin* / pharmacology
  • Amikacin* / therapeutic use
  • Animals
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Cyclophosphamide* / pharmacology
  • Disease Models, Animal*
  • Female
  • Imipenem / pharmacology
  • Imipenem / therapeutic use
  • Immunocompromised Host
  • Lung / drug effects
  • Lung / microbiology
  • Mice
  • Mycobacterium Infections, Nontuberculous* / drug therapy
  • Mycobacterium Infections, Nontuberculous* / microbiology
  • Mycobacterium abscessus* / drug effects

Substances

  • Cyclophosphamide
  • Anti-Bacterial Agents
  • Amikacin
  • Imipenem